P&K Skin Clinical Research Center and CNR Research Sign MOU for "Clinical Trial Development Collaboration"

[Asia Economy Reporter Hyunseok Yoo] P&K Skin Clinical Research Center, a skin human application testing institution, announced on the 10th that it has signed a strategic business agreement (MOU) with CRO (Contract Research Organization) C&R Research for collaboration in human application testing and clinical trial development.

P&K, which was listed on the KOSDAQ market last September, is the first skin human application testing institution established by a doctor in Korea. It focuses on verifying the efficacy and safety of cosmetics through human application tests. The company is expanding its business areas to health functional foods and beauty devices. By mainly collaborating with top-tier clients such as global companies, domestic conglomerates, and online brands, it has established an unrivaled position as the industry leader.

C&R Research is Korea’s first established clinical trial CRO and has successfully conducted over 1,600 projects over the past 24 years, making it the highest-level clinical specialized CRO in the country. It provides comprehensive clinical development services and regulatory approval solutions from early-phase clinical trials to post-approval clinical trials. Strengthening its platform function as a global clinical trial partner, it offers customized full-cycle product development solutions from initial product development to commercialization.

Through this agreement, both companies plan to build a strategic cooperation system including mutual technology information exchange, technical education, human application testing, consulting support related to clinical trial development, and joint sales, aiming to achieve the common goal of maximizing sales through a business win-win.

P&K expects expansion in the health functional food sector through collaboration with C&R Research. This will enhance global influence not only in cosmetics and beauty device human application testing but also in the health functional food field, which is anticipated to have a positive impact on future entry into the Chinese market.

Additionally, the two companies are expected to activate health functional food and skin clinical trials further by establishing a joint sales system. Moreover, for projects requiring clinical trials after human application testing, smoother progress is anticipated through the linkage of the two institutions.

Lee Hae-kwang, CEO of P&K, expressed expectations, saying, “The know-how and sales power of both companies, leaders in clinical trials, will create positive synergy, and competitiveness will rise together.”

This content was produced with the assistance of AI translation services.